Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing therapies that target Natural Killer T (NKT) cells for the treatment of inflammatory, fibrotic and autoimmune diseases. This news page aggregates company announcements, clinical updates and capital markets disclosures related to GRI Bio and the GRI stock.
Investors following GRI Bio’s news can track the progress of its lead program GRI-0621, an oral RARβγ agonist and iNKT activity inhibitor being developed for idiopathic pulmonary fibrosis (IPF). The company has reported interim and topline results from a Phase 2a randomized, double-blind, placebo-controlled trial in IPF, including safety and tolerability data, changes in collagen turnover biomarkers, signals of alveolar basement membrane repair and analyses of forced vital capacity (FVC). Additional releases describe immune profiling data showing iNKT inhibition and shifts toward an anti-fibrotic cytokine profile.
News items also cover interim biomarker and lung function analyses, recommendations from the Independent Data Monitoring Committee, and presentations at investor and industry conferences. These communications provide context on how GRI Bio interprets emerging clinical data and its plans for further development of GRI-0621.
Beyond clinical results, GRI Bio issues press releases on financing transactions, such as its December 2025 best efforts public offering of common stock, pre-funded warrants and Series F warrants, and related Nasdaq listing compliance updates. Governance and corporate actions, including equity incentive plan amendments and annual meeting matters, are reflected in associated SEC filings and news references.
By reviewing this GRI news feed, readers can monitor key developments in GRI Bio’s NKT cell–modulating pipeline, particularly in IPF and systemic lupus erythematosus, as well as follow capital raising activities and other material events that may be relevant to GRI stock research. Bookmark this page to access an organized stream of GRI Bio press releases and related market updates.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Marc Hertz will deliver a presentation on September 9, 2025, at 3:00 PM ET in New York. Management will also conduct one-on-one meetings with qualified investors during the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.
The virtual presentation will be delivered by CEO Marc Hertz, PhD on Wednesday, August 20, 2025 at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators, announced CEO Marc Hertz's participation in a Virtual Investor "What This Means" segment. During the presentation, Dr. Hertz discussed the company's recently announced 6-week interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF).
GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim biomarker data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The study, which has completed enrollment of approximately 35 subjects, showed that GRI-0621 treated patients demonstrated favorable reduction in fibrogenesis biomarkers and increased basement membrane remodeling.
The Independent Data Monitoring Committee (IDMC) has recommended continuing the study as planned, noting no safety concerns in the data reviewed. The trial remains blinded, with patients randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo. The company expects to report topline results in Q3 2025, with additional pulmonary function test data expected in the coming weeks.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Marc Hertz, PhD shared insights about his leadership journey, his commitment to the company, and his enthusiasm for GRI Bio's development programs. The presentation is now available for viewing on virtualinvestorco.com and the company's investor relations website.
GRI Bio (NASDAQ: GRI) has completed patient enrollment in its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The study enrolled approximately 35 subjects randomized in a 2:1 ratio to receive either GRI-0621 4.5mg or placebo once daily for 12 weeks.
The company reported positive interim safety results, with GRI-0621 demonstrating safety and tolerability in both 2-week (12 patients) and 6-week (24 patients) analyses. Notably, no hyperlipidemia was observed in treated patients, and interim biomarker results from the first 12 subjects at 2 weeks suggested potential anti-fibrotic effects.
The study's primary endpoint focuses on safety and tolerability after 12 weeks of treatment, with secondary endpoints including changes in serum biomarkers, pharmacokinetics, and pharmacodynamic activity. The company expects to report 6-week interim biomarker data in July 2025 and topline results in Q3 2025.
GRI Bio (NASDAQ: GRI) has reported positive interim safety results from its Phase 2a study of GRI-0621, a RAR-βɣ dual agonist for treating Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) found no safety concerns in the first 24 patients after 6 weeks of treatment and recommended continuing the study.
The trial involves approximately 36 subjects randomized in a 2:1 ratio, receiving either 4.5mg GRI-0621 or placebo daily for 12 weeks. The drug demonstrated favorable safety profiles with no adverse events related to hyperlipidemia. The company expects to report 6-week interim biomarker data in July 2025 and topline results in Q3 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor Closing Bell Series. CEO Marc Hertz, PhD will present on May 28, 2025, at 4:00 PM ET.
The event will include a corporate overview, business outlook, and a live Q&A session with investors. The presentation will be webcast live on the company's website and will remain accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in A.G.P.'s Annual Healthcare Company Showcase. CEO Marc Hertz, PhD will engage in a fireside chat on Wednesday, May 21, 2025, at 2:40 PM ET. The virtual event will be accessible via webcast through the Events page in the Investors section of GRI Bio's website.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
